The 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Adam J. Fein, Ph.D.
Drug Channels Institute

October 2019

Full report available at https://drugch.nl/wholesale
Copyright © 2019 by Pembroke Consulting, Inc., d/b/a Drug Channels Institute. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.


The complete End User License Agreement is available at: https://drugch.nl/2019-20EULA
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the CEO of Drug Channels Institute (DCI), a leading management educator for and about the pharmaceutical industry. DCI is a subsidiary of Pembroke Consulting, Inc.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, The Washington Post, Forbes, and many others.

His popular and influential Drug Channels website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. Drug Channels is the only place where you’ll find a serious discussion of PBMs, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and his undergraduate degree from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: afein@drugchannels.net

Visit Dr. Fein’s Drug Channels blog for the latest industry updates!

www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI) is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—into comprehensive, interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. These online learning tools explain highly complex economic and business data and concepts so you can:

• Make better decisions to achieve your business goals
• Improve relationships with key accounts
• Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

View a module list at http://drugchannelsinstitute.com/products/e-learning-modules/.

DCI can code and brand any module for your company's internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms, including iPads.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THE 2019-20 REPORT

For pharmaceutical wholesalers, 2019 brought relative stability after a volatile and challenging period. The industry is confronting a diverse set of business, political, and legal challenges, some of which have persisted for multiple years:

- Vertical and horizontal mergers and acquisitions are reshaping the pharmacy and PBM industries, leading to unprecedented consolidation and shakeout among wholesalers’ customer base. Wholesalers’ smaller pharmacy customers face mounting pressures on their prescription profits.

- Payers and PBMs are tightening their management of specialty drugs, putting pressure on such key wholesaler customer groups as independent specialty pharmacies, dispensing physician practices, and hospital pharmacies.

- List prices for brand-name drugs are growing at moderate rates compared to historical norms. Deflation in generic drug prices continues, though the rate of change has steadied.

- After years of delay, the market for provider-administered biosimilars has begun to develop, though wholesalers have yet to reap significant financial benefits.

- The federal government and multiple states are pursuing new policies aimed at importation of drugs intended for foreign markets.

- Wholesalers have ceased major acquisition activity. The large wholesalers have collectively written down $6 billion for their unsuccessful diversification efforts: AmerisourceBergen for its PharMEDIUM compounding services, Cardinal Health for its medical products manufacturing, and McKesson for its international distribution and pharmacy businesses.

- Regulatory efforts to remove the role of rebates in the drug channel system and reduce list price as a component of intermediary compensation failed. The prospects for legislative action remain highly uncertain.

- Wholesalers’ potential financial liabilities for the opioid crisis are becoming clearer, though their ultimate culpability for their role in the distribution of opioids is not known.

We project that U.S. drug distribution revenues for the Big Three public wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—will reach $481 billion in 2019. However, gross margin for drug distribution will decline for the fifth year, though the reduction in gross profits continues to be moderated by ongoing revenue growth.
Understanding an Evolving Channel

This 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our tenth edition—is the most comprehensive, fact-based tool for understanding and analyzing the U.S. pharmaceutical distribution industry. This definitive, nonpartisan resource thoroughly updates our annual exploration into the industry’s interactions with—and services for—other participants in our healthcare system. The report synthesizes a wealth of statistical data, research studies, financial information, and my own unique business consulting experience. It will aid pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.

This 2019-20 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. This new edition updates our annual analysis of each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models. This information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance. Where appropriate, financial data have been restated based on new disclosures since the previous edition.

What’s New in the 2019-20 Report

The 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors retains the structure that we used in last year’s edition, and the chapters correspond to those of previous editions. New material in this 2019-20 edition includes:

- A new Section 5.7 examines the financial factors that determine executive compensation at each of the Big Three wholesalers.

- Chapter 8 analyzes newly-disclosed financial information about Cardinal Health’s business segments and its relationship with UnitedHealth Group’s OptumRx business.

- Chapter 6, which covers forces of change facing drug distribution, has been expanded. Notable additions include:
  - The material in Section 6.1, which analyzes the pharmaceutical industry outlook, adds new material on wholesalers’ strategic reaction to these changes.
  - A new Section 6.2.5 discusses the potential impact of commercial importation of drugs intended for foreign markets.
  - Our analysis of the biosimilar market in Section 6.4 includes new data tracking adoption curves against four reference products.

- Chapter 3 contains new data about the structure and operations of the hospital market.

- There are 19 additional exhibits compared with the previous edition of this report.
Structure of the 2019-20 Report

The 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors analyzes the industry in three major sections, comprising nine total chapters.

PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES provides an integrated overview of the major themes that recur throughout our analysis. Each theme includes links to relevant chapters and sections within the full report.

SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS

- **Chapter 1: Industry Overview** (page 7) defines the industry, describes business differences between full-line wholesaling and specialty distribution, summarizes wholesalers’ obligations under the Drug Supply Chain Security Act (DSCSA), explains wholesalers’ channel roles, discusses, and quantifies the products that wholesalers sell. It also identifies the major full-line wholesalers and specialty distributors participants, and provides the our latest data on their market share and revenues.

- **Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies** (page 29) analyzes the pharmacy market—the customer group that accounts for the majority of wholesalers’ revenues. It covers wholesalers’ services for smaller pharmacies, wholesalers’ participation in the pharmacy-PBM relationship via Pharmacy Services Administrative Organizations (PSAOs), and interactions with pharmacy buying groups. The chapter then analyzes how wholesalers work with larger pharmacies, including our updated analysis of the large generic sourcing consortia between wholesalers and the largest pharmacies. **Section 2.4.** (page 55) analyzes wholesalers’ role in the distribution of patient-administered drugs that specialty pharmacies dispense. We also consider wholesaler-owned specialty pharmacies.

- **Chapter 3: Channel Role for Physician Office/Clincis and Hospitals** (page 62) examines channels for provider-administered medications, explains the buy-and-bill system for drugs administered in outpatient settings, and describes the role and functions that wholesalers perform for hospitals, including hospitals that participate in the 340B Drug Pricing Program. This chapter also provides an in-depth consideration of group purchasing organizations (GPOs) for both hospitals and physician practices.

SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS

- **Chapter 4: Wholesaler Profitability** (page 94) delves into the industry’s income statement economics to explain the underlying sources of drug distribution profits. We deconstruct buy-side and sell-side gross margin components, distinguish sell-side profits from specialty and traditional drugs, and explain distribution service agreements (DSAs) with manufacturers. We analyze overall gross margins and operating profits, and analyze
wholesalers’ gross profits of brand-name vs. generic drugs. This chapter also explains how brand-name drug price inflation affects wholesalers’ profits.

- **Chapter 5: Financial Stability and Cash Management** (page 120) provides a detailed analysis of the key metrics that illustrate wholesalers’ overall financial health. These include capital structures, debt (leverage), balance sheet assets, cash flow, return on invested capital, and stock market valuation and performance. Chapter 5 includes a new section for the 2019-20 edition that explains executive compensation at the Big Three wholesalers.

- **Chapter 6: Forces of Change for Drug Distribution** (page 138) updates our analysis of key industry trends that will impact the market structure and economics of the pharmaceutical wholesaling and specialty distribution industries. It presents the outlook for net prescription drug spending, brand-name and generic pricing, and reform of the drug channel system. Chapter 6 separately examines trends affecting pharmacy dispensing channels and buy-and-bill channels, including market, regulatory, and legislative issues. It also considers the current status and outlook for pharmacy-dispensed and provider-administered biosimilars.

**SECTION III: BIG THREE WHOLESALER COMPANY PROFILES**

In this section, we analyze the latest financial data and strategies of the largest public companies. Each chapter provides parallel examinations of the Big Three public wholesalers. We scrutinize each company’s business history, acquisitions and divestitures, business mix, profitability, largest customers, and company-specific business trends.

- **Chapter 7: AmerisourceBergen Corporation** (page 184)
- **Chapter 8: Cardinal Health** (Page 206)
- **Chapter 9: McKesson Corporation** (page 219)

**How to Use the 2019-20 Report**

*The chapters are self-contained and do not need to be read in order.* We include extensive internal references to help you navigate the entire document and customize it to your specific needs. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

There are more than 440 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the **Acronyms and Abbreviations** (page 240) used within it.
To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about The 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Adam J. Fein
October 2019

P.S. Click here for post-publication errata.
CONTENTS

PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES ................................................................. 1

SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS ................................................ 6

Chapter 1: Industry Overview ............................................................................................................. 7

1.1. Wholesale Industry Fundamentals ............................................................................................... 7

1.1.1. Defining Drug Wholesale Distribution .................................................................................. 7

1.1.2. Full-Line Wholesalers .......................................................................................................... 8

1.1.3. Specialty Distributors ........................................................................................................... 10

1.1.4. Regulation and Supply Chain Security .................................................................................. 12

1.2. The Products That Wholesalers Sell ............................................................................................ 15

1.2.1. Brand vs. Generic Drugs ..................................................................................................... 15

1.2.2. Route of Administration ..................................................................................................... 16

1.2.3. Traditional vs. Specialty Drugs ............................................................................................ 17

1.3. Overview of Wholesalers’ Channel Roles .................................................................................... 17

1.3.1. Physical Distribution ........................................................................................................... 18

1.3.2. Financial Intermediation ...................................................................................................... 19

1.3.3. Services for Pharmacies, Providers, and Manufacturers ..................................................... 20

1.3.4. Impact on Pharmacy and Provider Reimbursement ............................................................... 20

1.4. Industry Participants .................................................................................................................... 21

1.4.1. Big Three Wholesalers: Revenue and Growth Trends ............................................................ 21

1.4.2. Specialty Product Distribution Market Share ....................................................................... 24

1.4.3. Other Wholesale Market Participants .................................................................................. 26

Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies .................................................. 29

2.1. The Pharmacy Market .................................................................................................................. 30

2.1.1. Outpatient Dispensing Formats ............................................................................................ 30

2.1.2. Pharmacy Market Size and Structure ................................................................................ 32

2.2. Independent Pharmacies ............................................................................................................ 33

2.2.1. Industry Position and Wholesaler Market Shares ................................................................. 33

2.2.2. Wholesaler Services for Independent Pharmacies ............................................................... 37

2.2.3. Franchise Programs and Marketing Groups ......................................................................... 38

2.2.4. PSAOs and the Wholesalers’ Role in the Pharmacy-PBM Relationship ............................... 40

2.2.5. Pharmacy Group Purchasing Organizations and Wholesaler Relationships .................. 44

Drug Channels Institute
Prepublication Draft (9/3/19) – Subject to change
6.1.3. The Outlook for Generic Drug Prices ......................................................... 143
6.1.4. The Gross-To-Net Bubble and Risks to Wholesaler Compensation .................. 145
6.2. Evolution of Pharmacy Dispensing Channels .................................................. 149
  6.2.1. Pharmacy Market Evolution and Wholesaler Impact .................................. 149
  6.2.2. Specialty Pharmacy Growth and Concentration ......................................... 151
  6.2.3. Vertical Integration of PBMs and Insurers .................................................. 154
  6.2.4. Update on Amazon’s Potential Impact ...................................................... 156
  6.2.5. Importation From Foreign Markets .......................................................... 157
6.3. Evolution of Buy-and-Bill Channels ............................................................. 159
  6.3.1. Vertical Integration by Hospitals ............................................................... 159
  6.3.2. Specialty Pharmacies’ Role for Provider-Administered Drugs ..................... 165
  6.3.3. Update on Regulatory Changes to Medicare Part B ................................. 171
6.4. The Impact of Biosimilars on Wholesalers .................................................... 174
  6.4.1. 2019 Update on the Biosimilar Market .................................................... 174
  6.4.2. Biosimilars Under the Pharmacy Benefit .................................................. 175
  6.4.3. Biosimilars Under the Medical Benefit ...................................................... 177
SECTION III: BIG THREE WHOLESALER COMPANY PROFILES ............................... 183
Chapter 7: AmerisourceBergen Corporation ......................................................... 184
  7.1. Business Overview ....................................................................................... 184
    7.1.1. Company Information ............................................................................. 184
    7.1.2. Company History .................................................................................. 184
    7.1.3. Acquisitions and Divestitures ............................................................... 185
    7.1.4. Business Segments ............................................................................... 186
  7.2. Profitability ................................................................................................. 189
    7.2.1. Overall Pharmaceutical Distribution ..................................................... 189
    7.2.2. Profitability by Business Sub-Segment .................................................. 191
  7.3. Customers .................................................................................................. 193
    7.3.1. The 10 Largest Customers ..................................................................... 193
    7.3.2. Walgreens Boots Alliance .................................................................... 195
    7.3.3. Express Scripts ..................................................................................... 199
  7.4. Growth Trends ........................................................................................... 201
    7.4.1. Distribution Company Growth Trends .................................................. 201

9.4.2. McKesson Specialty Health..................................................................................234
9.4.3. McKesson Europe...............................................................................................235
9.4.4. McKesson Canada...............................................................................................238

Acronyms and Abbreviations.........................................................................................240

Endnotes.......................................................................................................................241
LIST OF EXHIBITS

Exhibit 1: Full-Line Wholesale Revenues, by Type of Customer, 2016 ................................................................. 9
Exhibit 2: Full-Line Wholesale, Inventory Levels vs. Product Sales, by Product Type, 2017 ................................. 9
Exhibit 3: Full-Line Wholesale, Inventory Levels and Product Sales, by Product Type, 2010 vs. 2016 .......... 10
Exhibit 4: Specialty Distributor Revenues, by Type of Customer, 2017 ................................................................. 11
Exhibit 5: Specialty Distributor Sales, by Therapeutic Area, 2017 ................................................................. 11
Exhibit 6: Distribution Center Operational Metrics, Full-Line Wholesalers vs. Specialty Distributors, 2017 .... 12
Exhibit 7: Timeline of DSCSA Requirements for Wholesale Distributors, 2013 to 2023 ................................. 13
Exhibit 8: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2002 to 2023 ................................. 16
Exhibit 9: Allowance for Doubtful Accounts at Big Three Wholesalers, by Company, 2019 ............................ 19
Exhibit 10: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, Calendar Year 2018 .......... 22
Exhibit 13: Specialty Product Distribution Revenues, by Division and Parent Company, 2018 ......................... 25
Exhibit 14: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs ...................................................................................................................... 29
Exhibit 15: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2018 ................................................................................................................................................ 32
Exhibit 16: Number of Independent Pharmacy Locations, 2001 to 2017 .......................................................... 34
Exhibit 17: Independent Pharmacies, Average Per-Prescription Gross Profits and Margins, 2013 to 2017 ...... 36
Exhibit 18: Estimated Drug Sales and Market Share with Independent Pharmacies, by Wholesaler, 2018 ...... 37
Exhibit 19: U.S. Pharmacy Franchise and Marketing Programs, 2018 ................................................................. 39
Exhibit 20: Customer Satisfaction With Pharmacies, by Dispensing Format and Company, 2019 ................. 40
Exhibit 21: Largest Pharmacy Services Administrative Organizations, by Members and Ownership, 2019 ...... 43
Exhibit 22: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Number of Pharmacies, 2019 ................................................................................................................................................ 45
Exhibit 23: Wholesaler Generic Source Programs, Number of SKUs and Manufacturers, 2011 to 2017 ........ 47
Exhibit 24: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2018 ........................................ 49
Exhibit 25: Alignment Between the Big Three Wholesalers and the Top Five Pharmacies ......................... 50
Exhibit 26: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2018 ......................................... 50
Exhibit 27: Share of U.S. Generic Purchasing Volume, by Organization, 2019 ................................................... 52
Exhibit 28: Specialty Drug Prescription Revenues, by Dispensing Format, 2018 .............................................. 56
Exhibit 29: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2018 .... 57
Exhibit 30: Alternative Channels to Specialty Pharmacies in Limited Dispensing Networks ....................... 60
Exhibit 31: Medical Benefit Spending on Provider-Administered Drugs, by Drug Category and Payer, 2017 .. 63
Exhibit 64: Annual Price Increases for Brand-Name Drugs, 2014 to 2018
Exhibit 65: Illustrative Value of a Wholesaler’s Buy-Side Fees with Alternative Brand-Name Pharmaceutical Price Inflation Scenarios
Exhibit 66: Illustrative Effect of Inventory Revaluation on a Wholesaler’s Gross Profit
Exhibit 67: Full-Line Wholesalers, Operating Expenses, by Category, 2017
Exhibit 68: Big Three Wholesalers, Drug Distribution Operating Profit As a Percentage of Revenues, 2015 to 2019
Exhibit 69: Big Three Wholesalers, Distribution Operating Profits As a Percentage of Gross Profits, 2019
Exhibit 70: Big Three Wholesalers, Total Debt Including Interest Payment, 2019
Exhibit 71: Big Three Wholesalers, Debt-to-EBITDA Ratio, FY2017 to FY2019
Exhibit 72: Big Three Wholesalers, Liquidity Ratios, FY2018
Exhibit 73: Big Three Wholesalers, Composition of Current Assets, 2019
Exhibit 74: Illustrative Wholesaler Cash Conversion Cycle for Brand-Name Drugs Sold to a Pharmacy Customer
Exhibit 75: Big Three Wholesalers, Cash Conversion Cycle, 2018
Exhibit 76: Big Three Wholesalers, Cash Conversion Cycle, 2013 to 2019
Exhibit 77: Big Three Wholesalers, Days of Sales in Inventory, 2015 to 2019
Exhibit 78: Wholesalers’ Days of Sales in Inventory, by Therapeutic Category, 2018
Exhibit 79: Big Three Wholesalers, Days Sales Outstanding, 2015 to 2019
Exhibit 80: Percentage of Wholesalers’ Trade Accounts Receivable and DSO for Largest Customers, 2018/2019
Exhibit 81: Big Three Wholesalers, Days Payable Outstanding, 2015 to 2019
Exhibit 82: Big Three Wholesalers, Dividends and Share Repurchases As a Percentage of Operating Cash Flow, FY2017 to FY2019
Exhibit 83: Big Three Wholesalers, Return on Invested Capital, 2015 to 2019
Exhibit 84: Forward Price-to-Earnings Ratio, Big Three Wholesalers vs. S&P 500, 2015 to 2019
Exhibit 85: One- and Five-Year Stock Price Performance, Big Three Wholesalers vs. Manufacturers and Overall Market
Exhibit 86: Components of CEO Compensation, Big Three Wholesalers, 2019
Exhibit 87: Financial Metrics Used for Annual Cash Incentive Compensation, Big Three Wholesalers, 2019
Exhibit 88: Financial Metrics Used for Long-Term Incentive Compensation, Big Three Wholesalers, 2019
Exhibit 89: Total U.S. Drug Purchases, Annual Total, 2014 to 2023
Exhibit 90: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, Oral vs. Injectable, 2015 to 2019
Exhibit 91: Change in List vs. Net Price, by Manufacturer, 2018
Exhibit 92: PrescriptionsDispensed and Prescription Revenues, by Dispensing Format, 2018
Exhibit 93: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2013 to 2023
Exhibit 94: Vertical Business Relationships Among the Larger Four PBMs, 2019

Exhibit 95: Summary of Relationships Among AmerisourceBergen, Cigna, Express Scripts, Prime Therapeutics, and Walgreens Boots Alliance ................................................................. 155
Exhibit 96: Percentage of Physician Practices Owned by a Hospital or Health System, by Medical Specialty, 2007 vs. 2017 ........................................................................................................ 159
Exhibit 97: Hospital-Employed Physicians, 2012 to 2018 ........................................ 160
Exhibit 98: Medicare Part B Spending on Provider-Administered Outpatient Drugs, by Location of Service, 2008 to 2018 ........................................................................................................ 162
Exhibit 99: Share of Medicare Part B Spending on Provider-Administered Outpatient Drugs, by Location of Service, 2008 to 2018 ................................................................. 163
Exhibit 100: Share of Specialty Distributor Revenues, by Customer Type, 2011 to 2016 ................................................................. 164
Exhibit 101: Use of Site-of-Care Management Programs for Provider-Administered Drugs, Commercial Health Plans, 2013 to 2017 ........................................................................................................ 165
Exhibit 102: Drug Sourcing for In-Practice Administration, by Practice Type and Source, 2018 ................................................................. 168
Exhibit 103: Drug Sourcing for In-Practice Administration, Physician Offices, 2010 vs. 2018 ................................................................. 168
Exhibit 104: FDA Approved Biosimilars, Patient-Administered Drugs, 2016 to 2019 ........................................................................................................ 176
Exhibit 105: FDA Approved Biosimilars, Provider-Administered Drugs, 2015 to 2019 ........................................................................................................ 178
Exhibit 106: Market Share of Provider-Administered Biosimilars, 2016 to 2019 ........................................................................................................ 179
Exhibit 107: AmerisourceBergen, Pharmaceutical Distribution Segment, Profitability Metrics, 2015 to 2019 ................................................................. 191
Exhibit 108: AmerisourceBergen, Estimated Revenues and Operating Profit, by Segment, FY2019E ................................................................. 193
Exhibit 110: Diplomat Pharmacy, Drug Purchases, by Supplier, 2012 to 2018 ........................................................................................................ 196
Exhibit 111: AmerisourceBergen, Revenues from Walgreens Boots Alliance, 2015 to 2019 ........................................................................................................ 198
Exhibit 112: AmerisourceBergen, Days Sales Outstanding from Walgreens and Express Scripts vs. All Other Customers, 2015 to 2019 ........................................................................................................ 199
Exhibit 113: AmerisourceBergen, Revenues from Express Scripts, 2015 to 2019 ........................................................................................................ 200
Exhibit 114: Express Scripts, Pharmacy Dispensing Revenues and Share of Pharmaceutical Purchases Through AmerisourceBergen, 2014 to 2019 ........................................................................................................ 201
Exhibit 115: AmerisourceBergen, Revenues by Major Business Segment and Customer, FY2013 vs. FY2018 ........................................................................................................ 203
Exhibit 117: AmerisourceBergen Specialty Businesses, Revenues and Growth, 2015 to 2019 ........................................................................................................ 205
Exhibit 118: Animal Health, by Distributor and Segment, 2018 ........................................................................................................ 206
Exhibit 119: Cardinal Health, Profitability Metrics, 2015 to 2019 ........................................................................................................ 207
Exhibit 120: Cardinal Health, Estimated Revenues and Operating Profit, by Segment, FY2019 ........................................................................................................ 208
Exhibit 122: Cardinal Health, Revenues from CVS Health, 2015 to 2019 ........................................................................................................ 210
Exhibit 123: Cardinal Health, Days Sales Outstanding from CVS Health and OptumRx vs. All Other Customers, 2015 to 2019 ........................................................................................................ 211
Exhibit 124: Cardinal Health, Revenues from OptumRx, 2015 to 2019 ........................................................................................................ 212

Exhibit 126: McKesson, Distribution Businesses, Gross and Segment Operating Profitability Metrics, 2016 to 2019.........................................................................................................................224
Exhibit 127: McKesson, Estimated Revenues and Operating Profit, by Segment, FY2018......................226
Exhibit 129: McKesson, Revenues from CVS Health, 2015 to 2019.................................................................229
Exhibit 130: McKesson, Days Sales Outstanding from CVS Health vs. All Other Customers, 2015 to 2019.....231
Exhibit 131: McKesson, Revenues from Rite Aid, 2015 to 2019........................................................................232
Exhibit 133: McKesson Health Mart, Store Count and Change, 2007 to 2018....................................................234
Exhibit 134: McKesson Europe, Revenues and Profit, by Operating Segment, 2019........................................236
Exhibit 135: Celesio, Revenues, by Operating Segment, 2016 to 2019.................................................................237
Exhibit 136: McKesson Canada, Revenues and Growth, 2015 to 2019............................................................238